Tourmaline Bio, Inc. (TRML)
$47.98+0.00%Close
BUYBULL · day 33
Key stats
- Market cap
- $1.2B
- Avg volume
- 925.8K
- Beta
- 1.58
- P/E (TTM)
- -26.80
- 1W
- +0.04%
- 1M
- +0.25%
- YTD
- +111.55%
- vs SPY 1W
- +1.23%
- vs SPY 1M
- -3.07%
- vs SPY YTD
- +99.80%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- ALDXSELLAldeyra Therapeutics, Inc.RECOVERYQ -4$1.52+0.00%
- BMEABUYBiomea Fusion, Inc.RECOVERYQ -5$1.59+16.06%
- CGTXBUYCognition Therapeutics, Inc.RECOVERYQ -11$0.98-2.00%
- NMRASELLNeumora Therapeutics, Inc. Common StockRECOVERYQ -28$1.53-6.13%
- RCKTSELLRocket Pharmaceuticals, Inc.RECOVERYQ 6$3.53+0.57%
- PFSABUYProfusa, Inc. Common StockCRISISQ -28$4.58-16.12%
- INMBBUYINmune Bio, Inc.RECOVERYQ 1$2.36+1.72%
- PPBTBUYPurple Biotech Ltd.RECOVERYQ -16$1.56-0.64%
- NCNABUYNuCana plcRECOVERYQ -21$1.47-3.29%
- SHPHBUYShuttle Pharmaceuticals Holdings, Inc.CRISISQ -35$3.52-6.38%
- PLRXBUYPliant Therapeutics, Inc.RECOVERYQ -7$1.14-1.72%
- HKPDSELLCellyan Biotechnology Co., LtdCRISISQ -24$0.37-9.76%
Industry peers
FMP comparable companies · ranked by market cap
- DNTHBUYDianthus Therapeutics, Inc.$6.1BBULLQ 4$109.51-0.93%
- TERNTerns Pharmaceuticals, Inc.$4.8B$52.95
- AMLXBUYAmylyx Pharmaceuticals, Inc.$4.4BRECOVERYQ 10$39.66-1.32%
- RLAYBUYRelay Therapeutics, Inc.$4.3BBULLQ 4$19.70+1.65%
- ELVNBUYEnliven Therapeutics, Inc.$4.2BBULLQ 15$58.92+2.22%
- PGENBUYPrecigen, Inc.$2.7BRECOVERYQ 9$7.44-0.42%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.8BRECOVERYQ 18$19.75-0.41%
- ORICBUYORIC Pharmaceuticals, Inc.$1.4BBULLQ 4$13.88-5.21%
- IMTXSELLImmatics N.V.$1.1BCRISISQ 8$8.55-2.69%
- WVESELLWave Life Sciences Ltd.$1.0BCRISISQ 9$5.25-3.21%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-10.3%
REV YoY-
ROE-17.1%
EPS YoY-
ROA-17.1%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-26.80
P/E FWD-
SECTOR PE22.62
INDUSTRY PE17.13
P/B4.77
P/FCF-
EV/EBITDA-24.55
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.06
ALTMAN Z-
CURR RATIO24.68
ND/EBITDA-
BETA1.58
Company news
Loading headlines…